These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 21688481)

  • 1. [Calcineurin inhibitor nephrotoxicity in renal allografts].
    Takeda A; Morozumi K
    Nihon Jinzo Gakkai Shi; 2011; 53(4):610-4. PubMed ID: 21688481
    [No Abstract]   [Full Text] [Related]  

  • 2. Calcineurin inhibitor toxicity in renal allografts: morphologic clues from protocol biopsies.
    Sharma A; Jain S; Gupta R; Guleria S; Agarwal S; Dinda A
    Indian J Pathol Microbiol; 2010; 53(4):651-7. PubMed ID: 21045386
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Primer: Histopathology of calcineurin-inhibitor toxicity in renal allografts.
    Liptak P; Ivanyi B
    Nat Clin Pract Nephrol; 2006 Jul; 2(7):398-404; quiz following 404. PubMed ID: 16932468
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The CARI guidelines. Calcineurin inhibitors in renal transplantation: nephrotoxicity and calcineurin inhibitors.
    Coates PT;
    Nephrology (Carlton); 2007 Feb; 12 Suppl 1():S85-7. PubMed ID: 17316286
    [No Abstract]   [Full Text] [Related]  

  • 5. Expression of CYP3A5 and P-glycoprotein in renal allografts with histological signs of calcineurin inhibitor nephrotoxicity.
    Metalidis C; Lerut E; Naesens M; Kuypers DR
    Transplantation; 2011 May; 91(10):1098-102. PubMed ID: 21544031
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Calcineurin inhibitor nephrotoxicity in nephrotic syndrome].
    Ogahara S; Hisano S; Saito T
    Nihon Jinzo Gakkai Shi; 2011; 53(4):615-9. PubMed ID: 21688482
    [No Abstract]   [Full Text] [Related]  

  • 7. Understanding the genetic basis for adverse drug effects: the calcineurin inhibitors.
    Bai JP; Lesko LJ; Burckart GJ
    Pharmacotherapy; 2010 Feb; 30(2):195-209. PubMed ID: 20099993
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chronic calcineurin inhibitor nephrotoxicity: reflections on an evolving paradigm.
    Gaston RS
    Clin J Am Soc Nephrol; 2009 Dec; 4(12):2029-34. PubMed ID: 19850771
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Calcineurin inhibitor nephrotoxicity.
    Naesens M; Kuypers DR; Sarwal M
    Clin J Am Soc Nephrol; 2009 Feb; 4(2):481-508. PubMed ID: 19218475
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Deciphering calcineurin inhibitor nephrotoxicity: a pharmacological approach.
    Pallet N; Legendre C
    Pharmacogenomics; 2010 Oct; 11(10):1491-501. PubMed ID: 21047207
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dual RAS therapy not on target, but fully alive.
    Lambers Heerspink HJ; de Zeeuw D
    Nephron Clin Pract; 2010; 116(2):c137-42. PubMed ID: 20516713
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential expression of tissue factor (TF) in calcineurin inhibitor-induced nephrotoxicity and rejection--implications for development of a possible diagnostic marker.
    Osterholm C; Veress B; Simanaitis M; Hedner U; Ekberg H
    Transpl Immunol; 2005 Dec; 15(2):165-72. PubMed ID: 16412961
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The CARI guidelines. Calcineurin inhibitors in renal transplantation: pregnancy, lactation and calcineurin inhibitors.
    Grimer M;
    Nephrology (Carlton); 2007 Feb; 12 Suppl 1():S98-S105. PubMed ID: 17316288
    [No Abstract]   [Full Text] [Related]  

  • 14. ACE gene D/D genotype as a risk factor for chronic nephrotoxicity from calcineurin inhibitors in liver transplant recipients.
    Gallon L; Akalin E; Lynch P; Rothberg L; Parker M; Schiano T; Abecassis M; Murphy B
    Transplantation; 2006 Feb; 81(3):463-8. PubMed ID: 16477235
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of stopping inhibitors of the renin-angiotensin system in patients with advanced chronic kidney disease.
    Ahmed AK; Kamath NS; El Kossi M; El Nahas AM
    Nephrol Dial Transplant; 2010 Dec; 25(12):3977-82. PubMed ID: 19820248
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The CARI guidelines. Calcineurin inhibitors in renal transplantation: adverse effects.
    Jose M;
    Nephrology (Carlton); 2007 Feb; 12 Suppl 1():S66-74. PubMed ID: 17316284
    [No Abstract]   [Full Text] [Related]  

  • 17. Is arteriolar vacuolization a predictor of calcineurin inhibitor nephrotoxicity?
    Horike K; Takeda A; Yamaguchi Y; Ogiyama Y; Yamauchi Y; Murata M; Kawaguchi T; Suzuki T; Otsuka Y; Inaguma D; Goto N; Watarai Y; Uchida K; Morozumi K
    Clin Transplant; 2011 Jul; 25 Suppl 23():23-7. PubMed ID: 21623910
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The pharmacogenetics of calcineurin inhibitor-related nephrotoxicity.
    Hesselink DA; Bouamar R; van Gelder T
    Ther Drug Monit; 2010 Aug; 32(4):387-93. PubMed ID: 20571464
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Calcineurin-inhibition Results in Upregulation of Local Renin and Subsequent Vascular Endothelial Growth Factor Production in Renal Collecting Ducts.
    Prókai Á; Csohány R; Sziksz E; Pap D; Balicza-Himer L; Boros S; Magda B; Vannay Á; Kis-Petik K; Fekete A; Peti-Peterdi J; Szabó AJ
    Transplantation; 2016 Feb; 100(2):325-333. PubMed ID: 26502369
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Renin mRNA expression and renal dysfunction in tacrolimus-induced acute nephrotoxicity.
    Nakatani T; Uchida J; Iwai T; Matsumura K; Naganuma T; Kuratsukuri K; Sugimura K
    Int J Mol Med; 2003 Jan; 11(1):75-8. PubMed ID: 12469222
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.